Literature DB >> 12796066

Clinical significance, pathogenesis, and management of postprandial hyperglycemia.

John E Gerich1.   

Abstract

It is well established that strict glycemic control (hemoglobin A1c <7.0%) can prevent the microvascular complications of diabetes mellitus. Recent studies indicate that elevated plasma glucose concentrations are an independent and clinically significant risk factor for cardiovascular disease in nondiabetic and diabetic individuals. Thus, isolated postprandial hyperglycemia (2-hour postprandial glucose level >140 mg/dL [>7.8 mmol/L]) in the face of normal fasting plasma glucose (<110 mg/dL [<6.1 mmol/L]) and normal hemoglobin A1c (<6.1%) values is associated with a 2-fold increased risk of death from cardiovascular disease. These observations imply that more strict glycemic control is required to prevent macrovascular disease than microvascular disease. This review summarizes epidemiologic and experimental studies linking postprandial hyperglycemia to cardiovascular disease and therapeutic approaches available and in development to treat this disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796066     DOI: 10.1001/archinte.163.11.1306

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  67 in total

Review 1.  Impact of postprandial glycaemia on health and prevention of disease.

Authors:  E E Blaak; J-M Antoine; D Benton; I Björck; L Bozzetto; F Brouns; M Diamant; L Dye; T Hulshof; J J Holst; D J Lamport; M Laville; C L Lawton; A Meheust; A Nilson; S Normand; A A Rivellese; S Theis; S S Torekov; S Vinoy
Journal:  Obes Rev       Date:  2012-07-11       Impact factor: 9.213

Review 2.  Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  [Variability of blood glucose concentration and short-term mortality in critically ill patient].

Authors:  S C Ley; D Kindgen-Milles
Journal:  Anaesthesist       Date:  2007-08       Impact factor: 1.041

Review 4.  Pathophysiology and management of diabetic gastropathy: a guide for endocrinologists.

Authors:  Paul Kuo; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.

Authors:  Boris P Kovatchev; John Crean; Anthony McCall
Journal:  Diabetes Technol Ther       Date:  2008-10       Impact factor: 6.118

Review 6.  Food protein-derived bioactive peptides in management of type 2 diabetes.

Authors:  Prasad Patil; Surajit Mandal; Sudhir Kumar Tomar; Santosh Anand
Journal:  Eur J Nutr       Date:  2015-07-08       Impact factor: 5.614

Review 7.  What are the best options for controlling prandial glycemia?

Authors:  Stephen Clement
Journal:  Curr Diab Rep       Date:  2009-10       Impact factor: 4.810

Review 8.  Regulation of Glucose Production in the Pathogenesis of Type 2 Diabetes.

Authors:  Ashot Sargsyan; Mark A Herman
Journal:  Curr Diab Rep       Date:  2019-08-03       Impact factor: 4.810

9.  Hypoglycemic effect of standardized Chrysanthemum zawadskii ethanol extract in high-fat diet/streptozotocin-induced diabetic mice and rats.

Authors:  Yang-Ji Kim; Hyun-Kyu Kim; Hak Sung Lee
Journal:  Food Sci Biotechnol       Date:  2018-05-26       Impact factor: 2.391

Review 10.  Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.

Authors:  D Giugliano; A Ceriello; E Razzoli; K Esposito
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.